Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Mouse PVRIG Has CD8+ T Cell-Specific Coinhibitory Functions and Dampens Antitumor Immunity.

Murter B, Pan X, Ophir E, Alteber Z, Azulay M, Sen R, Levy O, Dassa L, Vaknin I, Fridman-Kfir T, Salomon R, Ravet A, Tam A, Levin D, Vaknin Y, Tatirovsky E, Machlenkin A, Pardoll D, Ganguly S.

Cancer Immunol Res. 2019 Feb;7(2):244-256. doi: 10.1158/2326-6066.CIR-18-0460. Epub 2019 Jan 18.

PMID:
30659055
2.

PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function.

Whelan S, Ophir E, Kotturi MF, Levy O, Ganguly S, Leung L, Vaknin I, Kumar S, Dassa L, Hansen K, Bernados D, Murter B, Soni A, Taube JM, Fader AN, Wang TL, Shih IM, White M, Pardoll DM, Liang SC.

Cancer Immunol Res. 2019 Feb;7(2):257-268. doi: 10.1158/2326-6066.CIR-18-0442. Epub 2019 Jan 18.

PMID:
30659054
3.

The Human Cytomegalovirus Protein UL148A Downregulates the NK Cell-Activating Ligand MICA To Avoid NK Cell Attack.

Dassa L, Seidel E, Oiknine-Djian E, Yamin R, Wolf DG, Le-Trilling VTK, Mandelboim O.

J Virol. 2018 Aug 16;92(17). pii: e00162-18. doi: 10.1128/JVI.00162-18. Print 2018 Sep 1.

4.

ILDR2 Is a Novel B7-like Protein That Negatively Regulates T Cell Responses.

Hecht I, Toporik A, Podojil JR, Vaknin I, Cojocaru G, Oren A, Aizman E, Liang SC, Leung L, Dicken Y, Novik A, Marbach-Bar N, Elmesmari A, Tange C, Gilmour A, McIntyre D, Kurowska-Stolarska M, McNamee K, Leitner J, Greenwald S, Dassa L, Levine Z, Steinberger P, Williams RO, Miller SD, McInnes IB, Neria E, Rotman G.

J Immunol. 2018 Mar 15;200(6):2025-2037. doi: 10.4049/jimmunol.1700325. Epub 2018 Feb 5.

PMID:
29431694
5.

NK Cell Recognition of Candida glabrata through Binding of NKp46 and NCR1 to Fungal Ligands Epa1, Epa6, and Epa7.

Vitenshtein A, Charpak-Amikam Y, Yamin R, Bauman Y, Isaacson B, Stein N, Berhani O, Dassa L, Gamliel M, Gur C, Glasner A, Gomez C, Ben-Ami R, Osherov N, Cormack BP, Mandelboim O.

Cell Host Microbe. 2016 Oct 12;20(4):527-534. doi: 10.1016/j.chom.2016.09.008.

6.

Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL.

Yosef R, Pilpel N, Tokarsky-Amiel R, Biran A, Ovadya Y, Cohen S, Vadai E, Dassa L, Shahar E, Condiotti R, Ben-Porath I, Krizhanovsky V.

Nat Commun. 2016 Apr 6;7:11190. doi: 10.1038/ncomms11190.

7.

The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity.

Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O, Novik A, Levine Z, Beiman M, Dassa L, Achdout H, Stern-Ginossar N, Tsukerman P, Jonjic S, Mandelboim O.

Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17858-63. doi: 10.1073/pnas.0903474106. Epub 2009 Oct 7.

8.

A novel peptide agonist of formyl-peptide receptor-like 1 (ALX) displays anti-inflammatory and cardioprotective effects.

Hecht I, Rong J, Sampaio AL, Hermesh C, Rutledge C, Shemesh R, Toporik A, Beiman M, Dassa L, Niv H, Cojocaru G, Zauberman A, Rotman G, Perretti M, Vinten-Johansen J, Cohen Y.

J Pharmacol Exp Ther. 2009 Feb;328(2):426-34. doi: 10.1124/jpet.108.145821. Epub 2008 Nov 20.

PMID:
19023040
9.

A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway.

Tiran Z, Oren A, Hermesh C, Rotman G, Levine Z, Amitai H, Handelsman T, Beiman M, Chen A, Landesman-Milo D, Dassa L, Peres Y, Koifman C, Glezer S, Vidal-Finkelstein R, Bahat K, Pergam T, Israel C, Horev J, Tsarfaty I, Ayalon-Soffer M.

Clin Cancer Res. 2008 Jul 15;14(14):4612-21. doi: 10.1158/1078-0432.CCR-08-0108.

Supplemental Content

Support Center